HK Stock Market Move | AB&B BIO-TECH-B (02627) rises by over 19% Company officially included in the Hong Kong Stock Connect list Innovative technology route receives international recognition

AB&B BIO-TECH-B (02627) rose by more than 19%, reaching a 14.67% increase at the time of publication, at 68.8 Hong Kong dollars, with a trading volume of 50.6877 million Hong Kong dollars. On the news front, on the evening of March 6, the Shanghai Stock Exchange and Shenzhen Stock Exchange announced that AB&B BIO-TECH-B has been included in the list of securities eligible for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from March 9. Previously, AB&B BIO-TECH-B announced a profit surprise, with the company expecting annual operating revenue of approximately 446 million to 493 million yuan, an increase of about 71.8% to 89.9% year-on-year. It is worth mentioning that recently, the Zhonghui Bio's monkeypox mRNA vaccine has been granted clinical approval by the FDA. Following the approval of the respiratory syncytial virus mRNA vaccine for clinical use by the FDA, Zhonghui Bio has once again gained international recognition for its innovative technology. Currently, there is no approved monkeypox vaccine on the market domestically, and the vaccines approved internationally for emergency use to prevent monkeypox virus infection are based on attenuated and replication-deficient vaccine technology, with room for improvement in safety, immunogenicity, and production capacity.